ICCM Reports 89.4% 5-Year Recurrence-Free Rate for ≤3cm Kidney Tumors, 83.9% General Population, ProSense® Approved in U.S./Europe, ECIO 2026 Presentation
IceCure Medical Ltd. Ordinary Shares · Now $0.20
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS